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CLINICAL PRACTICE
Low-molecular-weight heparin versus Standard
heparin in general and orthopaedic surgery:
a meta-analysis
MICHAEL T. NURMOHAMED FRITS R. ROSENDAAL
HARRY R. BÜLLER EVELIEN DEKKER DAAN W. HOMMES
JAN P. VANDENBROUCKE ERNEST BRIET
Low-molecular-weight heparins (LMWHs) have
theoretical advantages over Standard heparin äs
postoperative thromboprophylactic agents. We
conducted a meta-analysis of studies reported
between 1984 and April, 1991, in which LMWHs
were compared with Standard heparin for
postoperative prophylaxis. We included only
randomised studies (reported in English, French, or
German) in which investigators compared currently
recommended doses of the agents and used
adequate screening techniques for deep vein
thrombosis.
For all surgical studies the relative risk (LMWH
versus Standard heparin) for deep vein thrombosis
was 0-74 (95% Cl 0-65-0-86), for pulmonary
embolism 0-43 (95% Cl 0-26-0-72), and for major
bleeding 0-98 (95% Cl 0-69-1-40). Comparable
relative risks were observed for the general and
orthopaedic surgery studies separately. When the
analysisforthe general surgery studies was hmited to
those of strong methodology, assessed by eight
criteria defined in advance, the benefit/risk ratio was
less favourable—relative risk for deep vein
thrombosis 0-91 (95% Cl 0-68-1-23), for major
bleeding 1 -32 (95% Cl 0-69-2-56).
There is at present no convincing evidence that in
general surgery patients LMWHs, compared with
Standard heparin, generate a clinically important
improvement in the benefit to risk ratio. However,
LMWHs may be preferable for orthopaedic surgery
patients, in view of the larger absolute risk reduction
for venous thrombosis.
Lernet 1992, 340:152-56
Introduction
Venous thrombosis is common in postoperative patients
not receiving prophylaxis with anticoagulants: deep vein
thrombosis (DVT) develops in about 50% of patients
undergoing major orthopaedic procedures and 25% of
patients having major general surgery.1 Therefore,
thromboprophylaxis is widely recommended in these
patient categories.2 Since 1972, several randomised
controlled trials äs well äs three meta-analyses have
documented the efficacy of unfractionated heparin.3"5
Compared with no treatmentj perioperative subcutaneous
heparin (usually 5000 IU twice or thrice daily) reduced the
incidence of DVT by about 70%, at the expense of an
absolute excess of major haemorrhage of about 1-2% (ie,
from a mean of 3-8% to a mean of 5-9% for general surgery
and from a mean of 2-9% to a mean of 3-5% for orthopaedic
surgery; relative increases 55% and 21%, respectively5)·
Low molecular weight heparins (LMWH) are fractions of
heparin with a mean molecular weight below 10 kDa. They
have negligible effects on conventional heparin-sensitive
clotting assays, such äs the activated partial thromboplastin
time,6·7 and their inhibitory effect on platelet function is
substantially less than that of unfractionated heparin.8 Thus,
LMWH might have a superior benefit to risk ratio.
Since 1984, numerous clinical trials with LMWH have
been performed in patients undergoing major surgical
procedures. To evaluate efficacy and safety, we have pooled
the results of individual trials to obtain valid and precise
estimates of the occurrence of thromboembolic and bleeding
complications.
Methode
Data collection and definitions
We sought to idenufy from the Medline database and Current
Contents all comparative tnals of perioperative prophylaxis against
DVT or pulmonary embolism with LMWH published in Enghsh,
French, or German between Jan l, 1984, and April 30, 1991; in
addiüon we scanned citations from the retneved articles and from
abstract books of recent Conferences. Authors of abstracts were
asked for complete manuscripts but no attempt was made to obtain
results from unpubhshed studies.
From these articles we selected those reporting on patients
undergoing general surgery (defined äs abdominothoracic or
gynaecological surgery) or orthopaedic surgery (defined äs elective
or traumanc hip surgery). The analysis in this report is hmited to
invesdgations in which LMWH was compared with unfractionated
heparin, both agents being given in the currently recommended
dose for the surgical indicarion. We did, however, include studies in
ADDRESSES Centre for Haemostasis. Thrombosis,
Atherosclerosis and Inflammation Research, Academic Medicat
Centre. Amsterdam, the Netherlands (M T Nurmohamed, MD,
H R Buller, MD, E Dekker, MD, D W Hommes, MD); Department of
Haematology, University Hospital Leiden (F R Rosendaal, MD,
E Briet, MD): Department of Clinical Epidemiology, University
Hospital Leiden, Leiden (F R Rosendaal, Prof J P Vandenbroucke,
MD) Correspondence to Dr M T Nurmohamed, Centre for Haemostasis,
Thrombosis, Atherosclerosis and Inflammation Research, F4-131,
Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, the
Netherlands
VOL 340: JULY 18, 1992 THE LANGET 153
^m
which unfracuonated heparin or LMWH was gi ven in combination
with dihydroergotamine or in which elastic stockings were used.
The first analysis was confined to general-surgery trials in which
expectant 125I-fibrinogen leg scanning was done in all patients and
served äs the endpoint for the diagnosis of DVT, irrespective of
whether confirmatory ascending contras: venography was
performed. From orthopaedic surgery trials we included only the
studies in which routine venography was used in all patients for
establishing the presence or absence of DVT, since in this category
of patients 12SI-leg scanning is inappropriate.9 Articles were assessed
by two independent investigators. For each treatment group they
extracted the rate of DVT (defined äs a positive leg scan or abnormal
venogram in general or orthopaedic patients, respectively); the rate
of fatal and non-fatal pulmonary embolism (the diagnosis was
accepted if one or more of the following methods or criteria were
applied in both study groups: necropsy, perfusion-ventilation
scanning, angiography, or clinical diagnosis); total mortality; and
major bleeding (defined äs clinically overt with one or more of the
following criteria: fall in haemoglobin of more than l -2 g/l, bleeding
necessitating reoperation or cessation of prophylaxis, or
retroperitoneal or intracranial bleeding). The definitions of these
outcomes were agreed upon in advance. In case of disagreemenr
between the two assessors a third investigator was consulted.
Assessment of methodological strength
In this analysis all studies, irrespective of the screening method
for DVT, were scored by two independent investigators on eight
predefined items that were considered indicative of methodological
strength.10 For each item either nil (not satisfied) or one point was
given. Subsequently, the scores were added to form an eight-point
scale of methodological strength. The items were (1) type of
publication (peer-reviewed füll paper, "in press" included); (2)
inclusion and exclusion criteria clearly described; (3) randomisation
method clearly specified; (4) clinical characteristics of the study
groups adequately described (ie, at least three of the following
characteristics had to be mentioned: age, sex, type of Operation,
presence of malignancies, duration of Operation, type of
anaesthesia); (5) description of bleeding complications; (6) accurate
diagnosis of DVT (ie, venography in orthopaedic surgery patients
and 125I-fibrinogen leg-scanning in all other patients; (7) blinded
end-point assessment; (8) adequate description of patients not
completing the study protocol. A study was considered to have a
streng methodology if it satisfied seven or eight of the Standards.
The analysis for efficacy and safety was done separately for the
studies with strong and weak methodology.
Statistical analysis
The studies were analysed by intention-to-treat. For each report
the relative risk and the 95% confidence interval (CI) were
calculated for the efScacy and safety of LMWH over unfractionated
heparin treatment. Subsequently, the data from the 2 x 2 tables
regarding treatment and outcomes within each study were
combined by the Mantel-Haenszel method. Overall 95% CIs were
calculated by the test-based method according to Mieranen.11
Results
A total of 24 orthopaedic and 34 general surgery studies
were identified in which low-molecular-weight heparin was
evaluated äs a thromboprophylactic agent: in 43 low-
molecular-weight heparin was compared with
unfractionated heparin (30 general surgery studies and 13
orthopaedic surgery). A total of 8 studies, 7 in general
surgery patients and l in orthopaedic surgery patients, used
dosages higher than those currently recommended and were
not included.13"19 For the analysis of efficacy and safety
another 12 studies (6 general surgery and 6 orthopaedic
surgery) were excluded beforehand because an inadequate
screening method was employed for detection of DVT.20-31
The remaining reports encompassed a total of 8172 patients,
with 6878 in the general surgery trials (17 studies) and 1294
TABLE l—OUTCOMES IN GENERALAND ORTHOPAEDIC
SURGERY STUDIES COMPARING UNFRACTIONATED HEPARIN
(UFH) WITH LOW-MOLECULAR-WEIGHT HEPARIN (LMWH)*
Surgical group and
outcome studied
General surgery
DVT
ΡΕ ,
Major bleeding
Orthopaedic surgery
DVT
PE
Major bleeding
No of patients
evaluated
LMWH
3467
2888
1977
672
590
672
UFH
3411
2843
1966
622
582
622
No of patients
with outcome
LMWH
184
9
52
93
10
6
UFH
230
20
51
132
24
8
RR (95% CI)
0 79 (0 65-0 95)
0 44 (0 21-0-95)
1 01 (0 70-1 48)
0 68 (0 54-0 86)
0 43 (0 22-0-82)
0-75 (0-26-2 14)
PE = mcludes both fatal and non-fatal pulmonary embolism
in the orthopaedic surgery trials (6 studies).3^54 For the
analysis of methodological strength we included all 35
studies in which currently recommended doses of LMWH
and Standard heparin were compared. Separate analysis for
the combination of Standard heparin or LMWH with or
without either dihydroergotamine or elastic stockings
yielded no significant differences (data not shown), so the
results of these studies were pooled with investigations in
which these additional prophylactic measures were not
used.
Deep vein thrombosis
The relative risk for DVT of LMWH over Standard
heparin for all surgical trials combined was 0-74 (95% CI
0-65-0-86). The relative risks for the general and
orthopaedic surgery studies separately were similar (RR
0-79; 95% CI 0-65-0-95 and RR 0-68; 95% CI 0-54-0-86,
respectively). The number of patients äs well äs the number
of events in the two surgical groups are given in table I. In
general surgery patients the mean incidence of DVT was
6-7% in patients receiving Standard heparin and 5-3% in
those receiving LMWH; in orthopaedic patients the
respective figures were 21-2% and 13-8%.
Pulmonary embolism (fatal and non-fatal) and total
mortality
The relative risk for all pulmonary emboli (fatal and
non-fatal) of LMWH over Standard heparin in the two
surgical groups together was 0-43 (95% CI 0-26-0-72) and
was approximately the same in general surgery and
orthopaedic patients (table l). The absolute mean incidence
of pulmonary embolism (fatal and non-fatal) was again
higher in the orthopaedic surgery trials—4-1% in the
patients receiving heparin, 1-7% in those receiving
LMWH. The corresponding incidences in the general
surgery studies were 0-70% and 0-31%.
In all studies combined there were 2 fatal pulmonary
emboli in LMWH patients and 9 in those receiving Standard
heparin; there was no significant difference in the total
number of deaths (20 in the LMWH group, 24 in the
unfractionated heparin group). No patients died of
haemorrhage.
Major bleeding
For all studies combined there was no difference in the
incidences of major bleeding (RR 0-98%; 95% CI 0-69-
1 -40). The relative risks of major bleeding were about the
same in the general and orthopaedic surgery trials (table II).
In the general surgery trials the absolute mean incidence of
major bleeding was 2-6% in each of the two treatment
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TABLE II—OUTCOMES IN GENERALAND ORTHOPAEDIC
SURGERYSTUDIES, SUBDIVIDED BY METHODOLOGICAL
STRENGTH
Surgical group and
outcome studied
General surgery
Strong methodology:
DVT
PE
Major bleeding
Weaker methodology:
DVT
PE
Major bleeding
Orthopaedic surgery
Strong methodology:
DVT
PE
Major bleeding
Weaker methodology:
DVT
PE
Major bleeding
No of patients
evaluated
LMWH
1137
1137
1137
3092
2363
1529
387
305
387
682
682
622
UFH
1127
1127
1127
3028
2310
1515
337
297
337
686
686
626
No of patients
with outcome
LMWH
76
5
20
117
6
46
67
15
6
112
2
7
UFH
83
8
15
169
16
53
85
20
5
138
6
5
RR (95% Cl)
0-91 (0-68-1-23)
062(0-21-1-87)
1 32 (0 69-2-56)
0-67 (0-54-0-85)
0 37 (0-15-0-90)
086(058-1-26)
0-75 (0-56-0-99)
076(0-41-1-41)
1 19 (0 36-3-90)
082(0-66-1-02)
0-33(0-07-1-51)
1-40(0-45-4-36)
groups. The absolute mean incidence of major haemorrhage
in the orthopaedic studies (occurring in a much smaller
number of patients) was 0-9% for LMWH and 1-3% for
unfractionated heparin.
Methodological strength
13 of the 35 heparin-controlled studies (8 general surgery
and 5 orthopaedic surgery) were classed äs having strong
methodology (table n). In those dealing with general
surgery the relative risk for DVT was less pronounced than
in studies with a weaker design. In the studies with strong
methodology, major haemorrhage occurred more
frequently in the LMWH treated patients whereas the
opposite was observed in the weaker studies.
In orthopaedic surgery studies the relative risk for DVT
did not differ with methodological strengtli; there were too
few patients for meaningful assessment of differences in
bleeding incidences (table n).
Discussion
Since subcutaneous low-dose heparin is the most widely
used form of thromboprophylaxis we restricted the present
analysis to comparisons of LMWH and unfractionated
heparin. Moreover, for the first analysis we considered only
trials with currently recommended doses of LMWH.
Inclusion of higherniose triels .of LMWH might lead to
incorrect judgments about efficacy and safety. We also
specified an appropriate screening method for DVT.
Beyond any doubt, contrast venography is the only accurate
method for diagnosis of symptornless DVT after hip
surgery.55 After general surgery, 125I-fibrinogen leg
scanning lacks specificity and is less sensitive than we might
wish but is still a satisfactory screening method in direct
comparative studies.9
Overall we observed a 25-30% lower incidence of DVT
in patients given LMWH than in those given unfractionated
heparin. The reductions were similar in the two surgical
groups, äs was reported by Collins et al5 in their analysis of
unfractionated heparin versus no treatment. It should
however, be noted that the absolute reduction in the rate of
DVT is much larger for patients undergoing orthopaedic
surgery. To prevent one additional episode of DVT after
hip surgery,56 LMWH must be given to 14 patients,
whereas for general surgery the number is 71. This contrast
becomes even more striking if one realises that the venous
thrombi in hip surgery patients tend to be larger and more
often located in the proximal veins. Moreover, the diagnosis
of DVT in the general surgery studies was based on an
abnormal leg scan, whereas the thrombi in the orthopaedic
studies were detected by contrast venography. The greater
efficacy of LMWH in the prevention of venous thrombi in
the leg is also reflected by the observed reduction in the
occurrence of fatal and/or non-fatal pulmonary emboli.
Again this effect is similar in the two surgical groups.
Contrary to expectations, use of LMWH was not associated
with a lower bleeding risk.
The reductions in venous thromboembolic complications
with LMWH in the general surgery trials proved to be
much lower in methodologically strong investigations than
in those with less stringent design. Part of the explanation
may be inaccurate assessment of venous thrombosis.
Furthermore, we observed a moderately increased
frequency of major bleeding with LMWH in the general
surgery studies with strong methodology. This suggests
differences in the reporting of haemorrhage. In the
orthopaedic studies no such differences were observed for
venous thrombosis, and no conclusions could be drawn
about bleeding.
Publication bias, äs a result of underreporting of smaller
trials with no significant effect, must always be considered äs
a possible explanation of the outcome in a meta-analysis.
However, "funnel plot" analysis of the distribution of the
various trial outcomes by the number of study patients
included did not suggest that such a bias was present.57
In our meta-analysis we did not differentiate between the
various LMWH preparations, since subgroup analysis for
each LMWH preparation would not yield enough patients
per treatment group to detect important differences.
Moreover, the differences between these preparations are
small and appear not to be clinically relevant. We have not
addressed the issue of cost-effectiveness and frequency of
administration of LMWH and Standard heparin, since it
was our aim only to compare the efficacy and safety of
LMWH with Standard heparin.
In summary, even the large body of data in this
meta-analysis does not permit unequivocal conclusions.
Some clinicians may feel that the overall risk reduction of
venous thrombosis in the absence of an overall effect on the
bleeding frequency makes LMWH preferable to Standard
heparin. In absolute numbers, this risk reduction would
especially benefit orthopaedic surgical patients. However,
since the overall analysis does not show the expected major
improvement in thrombosis prevention, others may argue
that more weight should be given to the analysis by
methodological strength, which indicated that LMWH
conferred litde additional thromboprophylactic effect and
may be associated with more bleeding in general surgery
patients.
H. R. B. is a recipient of a fellowship from the Royal Netherlands Academy
of Ans and Sciences.
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REVIEW ARTICLE
Protein processing in lysosomes: the new
therapeutic target in neurodegenerative disease
R. JOHN MAYER MICHAEL LANDON LAJOS LASZLO
GRAHAM LENNOX JAMES LÖWE
A little recognised feature of neurons is their large
complemenf of lysosomes. Studies of the
accumulation of the abnormal isoform of the prion
protein (PrPsc) in the prion encephalopathies and
the formation of ß/A4 protein from its precursor in
Alzheimer's disease suggest that generation of these
key proteins takes place in lysosome-related
organelles. The release of hydrolytic enzymes from
lysosomes may be a primary cause of neuronal
damage.
Although molecular genetic approaches have
identified protein mutations central to the main
neurodegenerative disease, cell biological
observations are now beginning to unravel the
intracellular pathways involved in the molecular
pathogenesis of neurodegeneration: äs a result, it is
now appropriate to consider therapeutic
manipulation of the lysosomal System äs an
approach to treatment.
Lancet 1992; 340:156-59
Introduction
Neurons do not replicate in adult life, so they need an
efficient way of turning over proteins and dealing with any
abnormal proteins. To this end they possess a very
well-developed lysosome systerh. Evidence is accumulating
to suggest that abortive attempts to degrade proteins within
this System lie at the centre of the pathogenesis of some of the
major neurodegenerative diseases of man. These include
Alzheimer disease and the prion encephalopathies such äs
Creutzfeldt-Jakob disease where abnormal amyloid (ß/A4)
and prion (PrPsc)proteins, respectively, are deposited in
and around neurons. This in turn opens up the possibility of
new therapeutic strategies, aimed at altering lysosomal
protein processing.
Lysosome system
Lysosomes are the most familiär part of the large System
of acid-containing vesicles that enable cells to digest
unwanted material. They are characterised by specific
hydrolases (eg, ß-glucuronidase) which are most active at
low pH. Other components of this acidic vesicle System
include endosomes (vesicles formed after membrane
intemalisation during receptor-mediated endocytosis),
multivesicular and tubulovesicular bodies (which may form
by the surface invagination of endosomes), autophagic
vacuoles (formed within cells to isolate unwanted
organelles), and nascent hydrolase-containing vesicles
derived from the protein-packaging Golgi apparatus.1
Recent evidence suggests that the lysosome System
interacts closely with cell stress proteins. Cell stress
proteins—also known äs heat-shock proteins (HSP) after
one form of cell stress used in early experiments—are highly
conserved and have roles in normal cell activity äs well äs in
the protective response to cell damage. They include
ubiquitin, a central co-factor in protein degradation, and
HSP 70,2 which acts äs a molecular "chaperone", facilitating
the folding and transport of proteins across different
compartments within the cell.3 Initially thought of äs
cytosolic proteins, both are also found within lysosome
related organelles. Immunogold electronmicroscopy has
shown that normal lysosomes contain both free ubiquitin4
and ubiquitin-protein conjugates" and that these
conjugates accumulate excessively in lysosomes whose
function has been compromised by drugs.8 The precise
function of ubiquitin and HSP 70 in lysosomes is not clear,
although it presumably relates to the regulation of protein
degradation. Certainly cells with a mutation of the ubiquitin
activating enzyme El can no longer degrade proteins in
lysosomes.9 In addition, ubiquitin and HSP 70 are useful
markers of the lysosome System in both health and disease.
Ubiquitin-protein conjugates in health and
disease
Deposits of ubiquitin-protein conjugates are seen within the
neuropil of the normal elderly human brain in numbers that
increase with age.10·11 These are nerve cell processes (neuntes)
packed with ubiquitin-immunoreactive lysosome-related dense
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